<DOC>
	<DOC>NCT00486720</DOC>
	<brief_summary>This study is to evaluate the efficacy, safety and tolerability of vorinostat in patients with lower risk Myelodysplastic Syndrome (MDS).</brief_summary>
	<brief_title>Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient is a male or female, at least 18 years of age with low or intermediate1 risk Myelodysplastic Syndrome (MDS) defined by the International Prognostic Scoring System Patient has previously untreated disease, or has received up to one prior treatment regimen for lowerrisk Myelodysplastic Syndrome Patient has a performance status of equal to or less than 2 on the Eastern Cooperative Oncology Group Performance Scale Patient must have adequate organ function Patient has clinical evidence of Central Nervous System (CNS) leukemia Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the study Patient had prior treatment with a histone deacetylase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>